Affymetrix (Santa Clara, California) Announces Research Collaboration with Massachusetts General Hospital to Validate and Develop New Oncology Biomarker Tests

Published: Jun 06, 2012

SANTA CLARA, Calif.--(BUSINESS WIRE)--Affymetrix, Inc. (NASDAQ:AFFX) today announced a research collaboration and licensing agreement with Massachusetts General Hospital (MGH) to co-develop new cancer biomarker tests using the Affymetrix’ QuantiGene® ViewRNA Assay platform*, an in situ hybridization assay capable of single transcript in single-cell detection. As part of this agreement, Affymetrix has the rights to commercialize the new biomarker tests as an outcome of this collaboration.

Back to news